X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24703) 24703
Publication (1845) 1845
Book Review (390) 390
Book Chapter (160) 160
Book / eBook (116) 116
Conference Proceeding (49) 49
Magazine Article (21) 21
Newsletter (9) 9
Dissertation (8) 8
Newspaper Article (8) 8
Transcript (4) 4
Reference (3) 3
Trade Publication Article (3) 3
Data Set (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21439) 21439
female (11002) 11002
male (10912) 10912
index medicus (10501) 10501
middle aged (8021) 8021
recombinant proteins - therapeutic use (7726) 7726
adult (7305) 7305
recombinant proteins (6792) 6792
animals (5817) 5817
aged (5360) 5360
treatment outcome (4686) 4686
recombinant proteins - adverse effects (3263) 3263
interferon-alpha - therapeutic use (3107) 3107
oncology (3079) 3079
hematology (2619) 2619
pharmacology & pharmacy (2618) 2618
therapy (2559) 2559
mice (2419) 2419
immunology (2362) 2362
recombinant proteins - administration & dosage (2334) 2334
drug therapy, combination (2326) 2326
antiviral agents - therapeutic use (2234) 2234
erythropoietin - therapeutic use (2194) 2194
adolescent (2182) 2182
care and treatment (2139) 2139
interferon-alpha - adverse effects (2133) 2133
health aspects (2087) 2087
cancer (1871) 1871
hepatitis c, chronic - drug therapy (1727) 1727
polyethylene glycols - therapeutic use (1678) 1678
ribavirin - therapeutic use (1673) 1673
medicine, research & experimental (1654) 1654
analysis (1625) 1625
time factors (1616) 1616
dose-response relationship, drug (1613) 1613
proteins (1573) 1573
research (1549) 1549
recombinant fusion proteins - therapeutic use (1502) 1502
child (1486) 1486
drug administration schedule (1463) 1463
gastroenterology & hepatology (1390) 1390
surgery (1384) 1384
interferon (1356) 1356
drug therapy (1346) 1346
prospective studies (1338) 1338
antiviral agents - adverse effects (1334) 1334
antineoplastic combined chemotherapy protocols - therapeutic use (1330) 1330
retrospective studies (1321) 1321
interferon-alpha - administration & dosage (1289) 1289
risk factors (1289) 1289
anemia (1275) 1275
aged, 80 and over (1269) 1269
chemotherapy (1252) 1252
safety (1249) 1249
medicine & public health (1247) 1247
anemia - drug therapy (1223) 1223
biotechnology & applied microbiology (1191) 1191
recombinant proteins - pharmacology (1191) 1191
expression (1185) 1185
transplantation (1173) 1173
immunotherapy (1132) 1132
recombinant-human-erythropoietin (1132) 1132
recombinant (1129) 1129
clinical trials as topic (1128) 1128
erythropoietin (1118) 1118
double-blind method (1102) 1102
hepatitis c (1092) 1092
double-blind (1090) 1090
young adult (1089) 1089
clinical trials (1068) 1068
medicine, general & internal (1061) 1061
antineoplastic combined chemotherapy protocols - adverse effects (1059) 1059
follow-up studies (1053) 1053
granulocyte colony-stimulating factor - therapeutic use (1039) 1039
rats (1031) 1031
efficacy (1027) 1027
ribavirin (1007) 1007
antineoplastic agents - adverse effects (978) 978
article (975) 975
antibodies (939) 939
biochemistry & molecular biology (937) 937
trial (937) 937
anemia - etiology (935) 935
antibodies, monoclonal - therapeutic use (907) 907
medicine (893) 893
polyethylene glycols - adverse effects (886) 886
urology & nephrology (873) 873
research article (867) 867
colony-stimulating factor (859) 859
hepacivirus - genetics (853) 853
child, preschool (833) 833
ribavirin - adverse effects (833) 833
combined modality therapy (822) 822
management (821) 821
antineoplastic agents - therapeutic use (820) 820
filgrastim (818) 818
infection (818) 818
disease models, animal (816) 816
erythropoietin - adverse effects (815) 815
abridged index medicus (810) 810
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (65) 65
UofT at Mississauga - Stacks (25) 25
UofT at Scarborough - Stacks (20) 20
Engineering & Comp. Sci. - Stacks (13) 13
UTL at Downsview - May be requested (11) 11
St. Michael's College (John M. Kelly) - 2nd Floor (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
St. Augustine's Seminary - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Law (Bora Laskin) - Stacks (5) 5
Robarts - Stacks (5) 5
Regis College - Stacks (4) 4
Online Resources - Online (3) 3
Earth Sciences (Noranda) - Stacks (2) 2
Victoria University E.J. Pratt - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
OISE - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (23918) 23918
German (213) 213
French (179) 179
Spanish (164) 164
Japanese (120) 120
Chinese (102) 102
Russian (74) 74
Italian (58) 58
Polish (25) 25
Czech (22) 22
Hungarian (16) 16
Dutch (13) 13
Portuguese (11) 11
Serbian (9) 9
Danish (7) 7
Korean (6) 6
Swedish (5) 5
Bulgarian (4) 4
Finnish (4) 4
Slovak (4) 4
Ukrainian (4) 4
Norwegian (3) 3
Turkish (3) 3
Hebrew (2) 2
Bosnian (1) 1
Croatian (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 12, Issue 12, p. CD001099
Journal Article
Journal Article
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article